KYTX

Conviction 65HealthcareScan · Thu, Jun 25, 2026

KYTX$8.20-4.87%

ResistanceSupportVol 14

Vol MA14 1.07M

Mar 26Apr 14May 1May 19Jun 8Jun 25

Kyverna Therapeutics, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.kyvernatx.com ↗

Price8.20

Change-4.87%

Gap+0.70%

Rel volume7.28×

Avg volume1.01M

Avg $ vol8.18M

SMA 208.07

SMA 508.83

SMA 2007.95

Price vs 50-7.18%

Price vs 200+3.12%

MA stackmixed

50/200 cross—

Supertrenddown · 9.23

RSI (14)48

MACD hist0.10

MACD crossbull · 7d

Stoch %K / %D58 / 81

ADX (14)13

+DI / −DI16 / 21

RSI divergence—

MACD divergence—

ATR %+6.42%

ADR %5.50%

52w high11.25

52w low2.55

From 52w high-27.11%

Above 52w low+221.57%

New 52w highNo

SqueezeOn · 1d

Bollinger width15.46%

%B0.60

Donchian pos52.49%

Donchian high8.89

Donchian low7.44

AVWAP (52w high)8.91

vs AVWAP high-7.99%

AVWAP (52w low)8.16

vs AVWAP low+0.55%

OBV trendFlat

Chaikin MF (20)-0.21

Today vs 20d7.28×

Avg vol (14d)1.07M

Avg vol (20d)1.01M

Avg $ vol (20d)8.18M

Market cap498.52M

RS 3m (vs SPY)+0.57%

RS 6m (vs SPY)+12.15%

RS line new highNo

Trend template5/8

Technical rank35.4

1 week+1.99%

1 month-4.76%

3 months+4.19%

6 months+0.86%

1 year+157.05%

YTD-6.50%

P/E-3.09

P/B2.55

P/S—

P/FCF-3.24

EPS-3.64

Div yield—

ROE-82.48%

ROA-62.76%

Debt/Eq—

Current8.15

EV/EBITDA-2.78

Gross margin—

Net margin—

Rev growth—

EPS growth-26.54%

Price target30.00

Target upside265.85%

Analyst ratingBuy

Institutional67.81%

Ent. value466.33M

Revenue—

Net income-39.73M

Gross profit—

Free cash flow-153.72M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out60.8M

Employees129

ListedThu, Feb 8, 2024

Free float35.7M

Float %59.1%

Short interest5.74M

Days to cover6.8d

Short volume34.2%

Squeeze score72 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.66 vs −$0.75

Last surprise+12.0% beat

Setup gradeB

Conviction65 / 100

Pattern quality—

Tech rank35.4 / 100

Group rank50 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance10.34

Support7.44

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in KYTX

All disclosures →

No recent disclosed trades by Congress in KYTX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in KYTX · 7 buys · 1 sell

Insider	Side	Shares	Value	Traded	Filed
CLARK IAN T Director · Stock Option (right to buy) · 2026-05-27	Grant	20.58K	$0	2026-05-27	2026-05-29
SEIDENBERG BETH C Director · Stock Option (right to buy) · 2026-05-27	Grant	20.58K	$0	2026-05-27	2026-05-29
Cohen Fred E Director · Common Stock · 2026-05-27	Grant	5.09K	$0	2026-05-27	2026-05-29
Shaw Christi Executive Chairperson · Common Stock · 2026-05-27	Tax	4.19K	$36K	2026-05-27	2026-05-29
Aktar Mert Director · Common Stock · 2026-05-27	Grant	5.09K	$0	2026-05-27	2026-05-29
Cohen Fred E Director · Common Stock · 2026-05-27	Other	—	—	2026-05-27	2026-05-29
SEIDENBERG BETH C Director · Common Stock · 2026-05-27	Other	—	—	2026-05-27	2026-05-29
Cohen Fred E Director · Stock Option (right to buy) · 2026-05-27	Grant	20.58K	$0	2026-05-27	2026-05-29
Aktar Mert Director · Stock Option (right to buy) · 2026-05-27	Grant	20.58K	$0	2026-05-27	2026-05-29
CLARK IAN T Director · Common Stock · 2026-05-27	Grant	5.09K	$0	2026-05-27	2026-05-29

SEC filings

EDGAR filings in KYTX · 1 recent

EDGAR →

8-K8-KTue, Jun 2, 2026

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.